Hepatitis Monthly

Published by: Kowsar

Evaluation of Direct Acting Antivirals Efficiency in Turkish Patients with Chronic Hepatitis C Under Strict Rules

Figen Sarıgul 1 , * , Murat Sayan 2 , 3 , Ulku User 1 and Nefise Oztoprak 1
Authors Information
1 Infectious Disease and Clinical Microbiology, Antalya Education and Research Hospital, Health Sciences University, Antalya, Turkey
2 PCR Unit, Clinical Laboratory, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey
3 Research Center of Experimental Health Sciences, Near East University, Nicosia, Northern Cyprus
Article information
  • Hepatitis Monthly: March 31, 2019, 19 (3); e62390
  • Published Online: March 18, 2019
  • Article Type: Research Article
  • Received: October 2, 2017
  • Revised: December 14, 2018
  • Accepted: February 8, 2019
  • DOI: 10.5812/hepatmon.62390

To Cite: Sarıgul F, Sayan M, User U, Oztoprak N. Evaluation of Direct Acting Antivirals Efficiency in Turkish Patients with Chronic Hepatitis C Under Strict Rules, Hepat Mon. 2019 ; 19(3):e62390. doi: 10.5812/hepatmon.62390.

Abstract
Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Footnotes
References
  • 1. Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: A community-based long-term prospective study. J Infect Dis. 2012;206(4):469-77. doi: 10.1093/infdis/jis385. [PubMed: 22811301].
  • 2. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study. Hepatology. 2007;45(3):579-87. doi: 10.1002/hep.21492. [PubMed: 17326216].
  • 3. Zare F, Fattahi MR, Sepehrimanesh M, Safarpour AR. Economic burden of hepatitis C virus infection in different stages of disease: A report from Southern Iran. Hepat Mon. 2016;16(4). e32654. doi: 10.5812/hepatmon.32654. [PubMed: 27257424]. [PubMed Central: PMC4887962].
  • 4. European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis C virus infection. J Hepatol. 2017;66(1):153-94. doi: 10.1016/j.jhep.2017.03.021.
  • 5. Bruno S, Di Marco V, Iavarone M, Roffi L, Crosignani A, Calvaruso V, et al. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. J Hepatol. 2016;64(6):1217-23. doi: 10.1016/j.jhep.2016.01.034. [PubMed: 27059129].
  • 6. Jaroszewicz J, Flisiak-Jackiewicz M, Lebensztejn D, Flisiak R. Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis. Expert Opin Investig Drugs. 2015;24(9):1229-39. doi: 10.1517/13543784.2015.1057568. [PubMed: 26122697].
  • 7. Fox DS, McGinnis JJ, Tonnu-Mihara IQ, McCombs JS. Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: Data from the Veterans administration. J Gastroenterol Hepatol. 2017;32(6):1136-42. doi: 10.1111/jgh.13652. [PubMed: 27869323].
  • 8. Terrault NA, Zeuzem S, Di Bisceglie AM, Lim JK, Pockros PJ, Frazier LM, et al. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. Gastroenterology. 2016;151(6):1131-1140 e5. doi: 10.1053/j.gastro.2016.08.004. [PubMed: 27565882]. [PubMed Central: PMC5300778].
  • 9. World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis. WHO Press through the WHO website; [cited 2018]. Available from: www.who.int/about/licensing/copyright_form/en/index.html.
  • 10. Rodriguez-Torres M, Lawitz E, Kowdley KV, Nelson DR, Dejesus E, McHutchison JG, et al. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial. J Hepatol. 2013;58(4):663-8. doi: 10.1016/j.jhep.2012.11.018. [PubMed: 23183528].
  • 11. Link JO, Taylor JG, Xu L, Mitchell M, Guo H, Liu H, et al. Discovery of ledipasvir (GS-5885): A potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem. 2014;57(5):2033-46. doi: 10.1021/jm401499g. [PubMed: 24320933].
  • 12. Krishnan P, Beyer J, Mistry N, Koev G, Reisch T, DeGoey D, et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother. 2015;59(2):979-87. doi: 10.1128/AAC.04226-14. [PubMed: 25451055]. [PubMed Central: PMC4335823].
  • 13. Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147(2):359-365 e1. doi: 10.1053/j.gastro.2014.04.045. [PubMed: 24818763].
  • 14. Lawitz E, Makara M, Akarca US, Thuluvath PJ, Preotescu LL, Varunok P, et al. Efficacy and safety of ombitasvir, paritaprevir, and ritonavir in an open-label study of patients with genotype 1b chronic hepatitis C virus infection with and without cirrhosis. Gastroenterology. 2015;149(4):971-80 e1. doi: 10.1053/j.gastro.2015.07.001. [PubMed: 26170136].
  • 15. Hezode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): A randomised, open-label trial. Lancet. 2015;385(9986):2502-9. doi: 10.1016/S0140-6736(15)60159-3. [PubMed: 25837829].
  • 16. EMA drug Safety Communication. EMA recommends avoidence of certain hepatitis C medicines and amiodarone together. 2018.
  • 17. Turkish Statistical Institute. Data of Turkish Statistical Institute in 2017. 2017, [cited 30 Jan 2017]. Available from: http://www.turkstat.gov.tr.
  • 18. Bruggmann P, Berg T, Ovrehus AL, Moreno C, Brandao Mello CE, Roudot-Thoraval F, et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat. 2014;21 Suppl 1:5-33. doi: 10.1111/jvh.12247. [PubMed: 24713004].
  • 19. Shamsdin SA, Sepehrimanesh M, Pezeshki B, Nejabat M. Seroprevalence of hepatitis B and C in patients with hemophilia: A single-centre descriptive study. Shiraz Med J. 2015;16(7). doi: 10.17795/semj24573.
  • 20. Fattahi MR, Safarpour A, Sepehrimanesh M, Hosseini Asl SM, Mohamaddoust F. The prevalence of hepatitis C virus infection and its related risk factors among the rural population of fars province, southern iran. Hepat Mon. 2015;15(2). e24734. doi: 10.5812/hepatmon.24734. [PubMed: 25788957]. [PubMed Central: PMC4350250].
  • 21. Karaca C, Cakaloglu Y, Demir K, Ozdil S, Kaymakoglu S, Badur S, et al. Risk factors for the transmission of hepatitis C virus infection in the Turkish population. Dig Dis Sci. 2006;51(2):365-9. doi: 10.1007/s10620-006-3139-6. [PubMed: 16534682].
  • 22. Kabakci Alagoz G, Karatayli SC, Karatayli E, Celik E, Keskin O, Dinc B, et al. Hepatitis C virus genotype distribution in Turkey remains unchanged after a decade: Performance of phylogenetic analysis of the NS5B, E1, and 5'UTR regions in genotyping efficiency. Turk J Gastroenterol. 2014;25(4):405-10. doi: 10.5152/tjg.2014.7083. [PubMed: 25254523].
  • 23. Dore GJ, Ward J, Thursz M. Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward). J Viral Hepat. 2014;21 Suppl 1:1-4. doi: 10.1111/jvh.12253. [PubMed: 24713003].
  • 24. Health Ministry of Turkey. Health implementation guideline. [cited 25 Mar 2017]. Available from: http://www.sgk.gov.tr.
  • 25. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22(6):696-9. doi: 10.1016/0168-8278(95)80226-6. [PubMed: 7560864].
  • 26. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889-98. doi: 10.1056/NEJMoa1402454. [PubMed: 24725239].
  • 27. Alqahtani SA, Afdhal N, Zeuzem S, Gordon SC, Mangia A, Kwo P, et al. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. Hepatology. 2015;62(1):25-30. doi: 10.1002/hep.27890. [PubMed: 25963890].
  • 28. Feld JJ, Moreno C, Trinh R, Tam E, Bourgeois S, Horsmans Y, et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. J Hepatol. 2016;64(2):301-7. doi: 10.1016/j.jhep.2015.10.005. [PubMed: 26476290].
  • 29. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483-93. doi: 10.1056/NEJMoa1316366. [PubMed: 24725238].
  • 30. Zoulim F, Liang TJ, Gerbes AL, Aghemo A, Deuffic-Burban S, Dusheiko G, et al. Hepatitis C virus treatment in the real world: Optimising treatment and access to therapies. Gut. 2015;64(11):1824-33. doi: 10.1136/gutjnl-2015-310421. [PubMed: 26449729]. [PubMed Central: PMC5993679].
  • 31. Gondeau C, Pageaux GP, Larrey D. Hepatitis C virus infection: Are there still specific problems with genotype 3? World J Gastroenterol. 2015;21(42):12101-13. doi: 10.3748/wjg.v21.i42.12101. [PubMed: 26576095]. [PubMed Central: PMC4641128].
  • 32. American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance: Recommendations for testing, managing, and treating hepatitis C. Alexandria and Arlington, VA: AASLD and IDSA; [cited March 15, 2017]. Available from: www.hcvguidelines.org.
  • 33. Kliemann DA, Tovo CV, da Veiga AB, de Mattos AA, Wood C. Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database. World J Gastroenterol. 2016;22(40):8910-7. doi: 10.3748/wjg.v22.i40.8910. [PubMed: 27833382]. [PubMed Central: PMC5083796].
  • 34. Andre-Garnier E, Ribeyrol O, Gournay J, Besse B, Coste-Burel M, Mabille-Archambeaud I, et al. Emergence of HCV resistance-associated variants in patients failing sofosbuvir-based regimens: An observational cohort. Antivir Ther. 2016;21(7):611-9. doi: 10.3851/IMP3053. [PubMed: 27128103].
  • 35. Sargin Altunok E, Sayan M, Akhan S, Aygen B, Yildiz O, Tekin Koruk S, et al. Protease inhibitors drug resistance mutations in turkish patients with chronic hepatitis C. Int J Infect Dis. 2016;50:1-5. doi: 10.1016/j.ijid.2016.07.003.
  • 36. Sanlidag T, Sayan M, Akcali S, Kasap E, Buran T, Arikan A. [Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1]. Mikrobiyol Bul. 2017;51(2):145-55. Turkish. [PubMed: 28566078].
  • 37. Robaeys G, Bielen R, Azar DG, Razavi H, Nevens F. Global genotype distribution of hepatitis C viral infection among people who inject drugs. J Hepatol. 2016;65(6):1094-103. doi: 10.1016/j.jhep.2016.07.042. [PubMed: 27520879].
  • 38. Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, et al. Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: An economic analysis. PLoS Med. 2016;13(5). e1002032. doi: 10.1371/journal.pmed.1002032. [PubMed: 27243629]. [PubMed Central: PMC4886962].
  • 39. Loggi E, Gitto S, Galli S, Minichiello M, Conti F, Grandini E, et al. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice. J Clin Virol. 2017;93:66-70. doi: 10.1016/j.jcv.2017.05.021. [PubMed: 28654775].
  • 40. Londono MC, Carrion JA, Forns X. Letter: hepatitis B reactivation in patients with chronic hepatitis C during direct-acting antiviral therapy-authors' reply. Aliment Pharmacol Ther. 2017;45(12):1559-60. doi: 10.1111/apt.14104. [PubMed: 28503869].
  • 41. Honer Zu Siederdissen C, Maasoumy B, Marra F, Deterding K, Port K, Manns MP, et al. Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort. Clin Infect Dis. 2016;62(5):561-7. doi: 10.1093/cid/civ973. [PubMed: 26611779].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments